Drug Trial Radar · NCT07572123
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
374
Planned (sponsor's estimate)
Start
Dec 4, 2026
Primary completion
Mar 31, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- May 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). In addition, the phase III trial will compare the effect of pembrolizumab after HDT-ASCT to standard of care HDT-ASCT alone in high-risk patients with relapsed or refractory classic Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. An ASCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving HDT before an ASCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Radiation therapy (RT) uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving brentuximab vedotin and nivolumab after radiation may be safe, tolerable and more effective than standard of care HDT-ASCT in treating patients with standard risk relapsed or refractory classic Hodgkin lymphoma. In addition, giving pembrolizumab after standard of care HDT-ASCT may be safe and tolerable and more effective than HDT-ASCT alone in treating high-risk patients with relapsed or refractory classic Hodgkin lymphoma.
Conditions
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
Interventions
3-Dimensional Conformal Radiation TherapyRadiation
Undergo 3DCRT
Autologous Hematopoietic Stem Cell TransplantationProcedure
Undergo ASCT
Biospecimen CollectionProcedure
Undergo blood sample collection
Brentuximab VedotinDrug
Given IV
Computed TomographyProcedure
Undergo CT and PET/CT
High Dose ChemotherapyDrug
Receive HDT
Intensity-Modulated Radiation TherapyRadiation
Undergo IMRT
NivolumabBiological
Given IV
PembrolizumabBiological
Given IV
Pencil Beam ScanningRadiation
Undergo pencil beam proton RT
Positron Emission TomographyProcedure
Undergo PET/CT
Salvage TherapyProcedure
Receive standard of care salvage therapy
Scattering Proton Beam TherapyRadiation
Undergo passive scattering proton RT
TomotherapyRadiation
Undergo tomotherapy
Uniform Active Scanning Proton Beam TherapyRadiation
Undergo uniform scanning proton RT
Volume Modulated Arc TherapyRadiation
Undergo VMAT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) (Standard risk cohort)Time frame: From randomization to progression or death without documented progression, assessed up to 15 years
- PFS (High-risk cohort)Time frame: From randomization to progression or death without documented progression, assessed up to 15 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.